Business · 27/02/2003Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for Starlix Patent Extension
Summary
The Food and Drug Administration has officially confirmed the regulatory review period for the patent extension of Starlix, a human drug product, as required by law following a submission to the Director of Patents and Trademarks at the Department of Commerce.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →